Triple-negative breast cancer (TNBC), accounting for 15–20% of all breast cancers (BC), is defined by the absence of oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) expression on cancer cells [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.